BCR-ABL (Ph)-like acute leukemia—Pathogenesis, diagnosis and therapeutic options

Yishai Ofran, Shai Izraeli

Research output: Contribution to journalReview articlepeer-review


Recent comprehensive genetic studies revealed numerous genetic aberrations underlying a group of high-risk leukemias that share a specific activated kinase gene expression pattern. These ALLs were first recognized by the expression profile similar to that of Philadelphia chromosome-positive ALL and currently can be sub-classified by the main aberrantly activated kinase in the leukemic cells. We herein review the biological mechanisms and diagnostic and clinical challenges presented by these leukemias.

Original languageEnglish
Pages (from-to)11-16
Number of pages6
JournalBlood Reviews
Issue number2
StatePublished - 1 Mar 2017


  • BCR-ABL-like ALL
  • JAK inhibitors
  • Kinase-driven ALL
  • Ph-like ALL
  • Tyrosine kinase inhibitors


Dive into the research topics of 'BCR-ABL (Ph)-like acute leukemia—Pathogenesis, diagnosis and therapeutic options'. Together they form a unique fingerprint.

Cite this